Neal Eigler
Cedars-Sinai Heart Institute / ACRO Service Providor to V-Wave Ltd / J&J MedTech
ארצות הברית
Neal Eigler, MD, is a cardiologist, medical-device innovator, and entrepreneur. A UCLA and Yale graduate, he is a Professor of Medicine at UCLA and longtime Cedars-Sinai faculty member. He has authored more than 150 peer-reviewed papers and holds more than 75 US patents. As CEO of V-Wave, he led development of the Ventura interatrial shunt and the RELIEVE-HF program, including its randomized, double-blind, sham-controlled pivotal trial. V-Wave was acquired by Johnson & Johnson in 2024; he now serves as a Senior Advisor.
Neal Eigler, MD, is a cardiologist, medical-device innovator, and entrepreneur. He earned a BS in Cybernetics from UCLA in 1974 and an MD from Yale University School of Medicine in 1978. He completed residency, chief residency, and cardiology fellowship at Cedars-Sinai Medical Center and is board certified in internal medicine, cardiovascular disease, and interventional cardiology. He attained the rank of Professor of Medicine at UCLA in 1997 and served as Co-Director of the Cedars-Sinai Cardiac Catheterization Laboratory from 1985 to 2006. He remains on the faculty of the Cedars-Sinai Smidt Heart Institute. Over a biomedical research career spanning more than 50 years, Dr. Eigler has authored more than 150 peer-reviewed publications, served as principal investigator on three competitive NHLBI grants, and been named on more than 75 issued US patents. His work has focused on digital cardiovascular imaging and the development and clinical evaluation of interventional and implantable cardiovascular devices. Dr. Eigler has helped build early-stage medical-device companies since 1988. He co-founded Progressive Angioplasty Systems, served as Chief Medical Officer of Conor Medsystems, and co-founded and led Savacor, which developed implantable left atrial pressure monitoring and physician-directed patient self-management for heart failure. In 2015, he became CEO of V-Wave. He led development of the Ventura interatrial shunt and the RELIEVE-HF program, including the randomized, double-blind, sham-controlled pivotal trial evaluating interatrial shunt therapy across the spectrum of heart failure. V-Wave raised $196 million and was acquired by Johnson & Johnson in 2024 for $650 million. Dr. Eigler now serves as a Senior Advisor to Johnson & Johnson.